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Edited by Francesc PosasAbstract Sma and MAD-related protein 3 (Smad3) plays a key
role in the intracellular signaling of the transforming growth fac-
tor-b (TGF-b) family of growth factors, which exhibits a diverse
set of cellular responses, including cell proliferation and diﬀeren-
tiation. Smad3 has the N-terminal Mad homology (MH) 1 and
the C-terminal MH2 domains. MH2 domain is essential for
the TGF-b-induced transcriptional activation, because the
MH2 domain of Smad3 is involved in the interactions with sev-
eral transcriptional cofactors as well as the type I TGF-b recep-
tor (TbR-I). In this study, we examined the roles for four lysine
residues (Lys-333, Lys-341, Lys-378, and Lys-409) in the Smad3
MH2 domain. Mutation of the lysine (K)-378 to arginine (R)
(K378R) abolished the interaction with TbR-I, phosphorylation,
transcriptional activation by an active TbR-I. The K341R mu-
tant also failed to stimulate TGF-b-induced transcription by rest-
ing in the cytoplasm. However, the K409R mutant showed a
higher transcriptional activity by stronger interactions with co-
activators, such as p300/CBP. Furthermore, both the K341R
and K378R mutants act as dominant-negative inhibitors in the
TGF-b-induced target genes of endogenous TGF-b signal. Thus,
the lysine residues of Smad3 MH2 domain play important roles
in the transcriptional regulation of TGF-b signals through
TbR-I.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transforming growth factor-b (TGF-b) family of growth
factors regulates diverse biological processes. TGF-b inhibits
proliferation of epithelial, endothelial and haematopoieticAbbreviations: TGF, transforming growth factor; Smad, Sma and
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doi:10.1016/j.febslet.2005.04.023cells, regulates the diﬀerentiation of immune, neuronal, mesen-
chymal and epithelial cell types and modulates their apoptotic
response [1–3]. TGF-b signaling is mediated through cell mem-
brane transmembrane receptors located at the cell surface
(TGF-b receptors, TbRs) that are serine/threonine kinases,
which in turn use the highly conserved members of the Sma
and MAD-related protein (Smad) family of transcription fac-
tors to transduce their signals to the nucleus [4,5]. Two of
the receptor-regulated Smads (R-Smads), Smad2 and Smad3,
transduce signals for TGF-b. Co-Smad, Smad4, on the other
hand, acts as a heterodimeric partner for Smad2 and Smad3
for eﬃcient DNA binding and transcriptional activation
[6,7]. When TbRs are activated by the binding of their cognate
ligands, Smad 2 and Smad3 are phosphorylated by the TbR-I
serine-threonine kinase. Phosphorylated Smad2 and Smad3
then form stable hetero-complexes with Smad4 that translo-
cate into the nucleus and activate transcription. Smad7, one
of inhibitory Smads (I-Smads), stably interacts with activated
TbR-I and inhibits TGF-b signal [8–10].
Whereas phosphorylation plays a central role in the activa-
tion of the Smad pathway, recent studies demonstrate that
other types of post-transcriptional modiﬁcations of lysine res-
idues on Smads are also critical for TGF-b signals [11,12].
Ubiquitylation occurs by attachment of one or several ubiqui-
tin polypeptides to lysine residues of target proteins [13]. Pro-
teasomal degradation of ubiquitinated R-Smads has been
reported to be important for the maintenance of their steady
state levels and for the shutdown of the activated Smad path-
way after execution of its transcriptional roles [14]. Further-
more, I-Smads act as adaptor proteins that mediate
ubiquitination and degradation of TbR-I [15]. Ubiquitination
of Smad4 has been also reported to occur only in cancer cells
and is thought to be associated with oncogenic mutations in
the Mad homology (MH) 1 domain that lead to Smad4 inac-
tivation [16,17]. Recently, Lys-507 in Smad4-MH2 domain,
which participates in the C-terminal phosphoserine recogni-
tion, has been also identiﬁed as a major target for ubiquitina-
tion [18].
Sumoylation occurs by the covalent attachment of SUMO, a
ubiquitin-related polypeptide, to lysine residues [19]. Sumoyla-
tion also regulates the functions of a target protein by chang-
ing the subcellular localization, protein–protein interactions,
and/or stability [20]. In the previous study, we demonstrated
direct physical and functional interactions between Smad3
and protein inhibitor of activated STATy (PIASy) [5].
PIASy-mediated sumolyation of Smad3 in the presence of
Ubc9 and SUMO-1. We also demonstrated that PIASy theblished by Elsevier B.V. All rights reserved.
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PIASy-mediated suppression of Smad activity and the seques-
tration of Smad in nuclear bodies [21]. PIAS family E3 ligases
also induced sumoylation of lysine residues on Smad4 and
modify TGF-b family signals [22–24].
Acetylation is also known to be a dynamic post-translational
modiﬁcation of lysine residues. Proteins with intrinsic histone
acetyltransferase (HAT) activity act as transcriptional co-acti-
vators by acetylating histones and thereby induce an open
chromatin conformation, which allows the transcriptional
machinery access to promoters [25]. CBP/p300 and P/CAF
proteins interact with a large number of transcription factors,
such as the Smads [26–30], as well as components of the basic
transcriptional machinery. Acetylation of Smad7 on lysine res-
idues by p300 has been also reported [31]. Acetylation or muta-
tion of these lysine residues stabilizes Smad7 and protects it
from TGF-b-induced degradation.
In this report, we show the roles of four lysine residues in the
Smad3-MH2 domain in TGF-b signaling. We introduced
mutations to lysine residues within the Smad3-MH2 domain,
which were predicted to play important roles in interactions
with the receptor complexes and cofactors, and examined their
capabilities of binding to TbR-I as well as of transcriptional
activation of TGF-b signal. The mutation of Lys-341 and
Lys-378 showed a marked decrease of transcriptional activity
by an active TbR-I. The mutation of Lys-378 abolished the
binding ability to TbR-I and phosphorylation by TbR-I. How-
ever, the mutation of Lys-341 showed the normal binding abil-
ity to TbR-I and phosphorylation by TbR-I, but failed to
translocate into nucleus by TGF-b signal, suggesting Lys-341
is essential for nuclear translocation of Smad3. Contrarily,
the mutation of Lys-409 showed an enhanced transcriptional
activation through a stronger interaction with co-activators,
CBP/p300. These results suggest that the lysine residues of
Smad3-MH2 domain play important roles in the TGF-b
superfamily signals through interactions with receptor com-
plexes and co-regulators.2. Materials and methods
2.1. Reagents and antibodies
Human recombinant TGF-b1 was purchased from Strathmann
Biotech GmbH (Hamburg, Germany). Expression vectors, FLAG-
tagged murine Smad3, Smad4 [28], p300, and Ski [32] were kindly
provided by Dr. K. Miyazono (Tokyo University, Tokyo, Japan).
TbR-I (T204D), p3TP-LUC [33], CBP, SUMO-1, HA-tagged PIASy
[34] and FLAG-SMRT [35] were kindly provided by Dr. J. Massague´
(Memorial Sloan-Kettering Cancer Center, New York, NY), Dr. H.
Ariga, Dr. T. Taira (Hokkaido University, Sapporo, Japan) and
Dr. H. Nakajima (Inst. Mol. Cell. Biosci., Tokyo University, Tokyo,
Japan), respectively. Smad3 K333R, K341R, K378R and K409R mu-
tant constructs were generated by PCR methods and sequenced (pri-
mer sequences are available upon request). To obtain mammalian
expression vectors for glutathione S-transferase (GST)-fusion
Smad3-MH2 (GST-Smad3-MH2) K333R, K341R, K378R and
K409R mutants, Smad3-MH2 K333R, K341R, K378R or K409R
mutant fragments were generated by PCR methods and sequenced
(primer sequences are available upon request) and inserted into
pEBgs vector [36]. Anti-HA, anti-Myc, anti-GST, anti-phospho-
Smad3 (Ser 433/435), and anti-CBP antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-FLAG M2 anti-
body was purchased from Sigma (St. Louis, MO). Anti-SUMO-1
antibody was purchased from Medical & Biological Laboratories
(Nagoya, Japan). Anti-acetylated lysine antibody was purchased from
Cell Signaling TECHNOLOGY (Beverly, MA).2.2. Cell culture, transfection and luciferase assays
Human hepatoma cell line, Hep3B, was cultured in Dulbeccos mod-
iﬁed Eagle medium (DMEM) supplemented with 10% fetal bovine ser-
um (FBS). Hep3B cells were transfected with the wild-type Smad3
(Smad3 WT), Smad3 K333R, K341R, K378R or K409R mutant and
using jetPEI (PolyPlus-transfection, Strasbourg, France) according to
the manufacturers instructions. Stable Hep3B cell transformants were
selected with 500 lg/ml G418 (Sigma). Hep3B cells were transfected
with p3TP-LUC using jetPEI. Forty-eight hours after transfection,
the cells were treated with TGF-b (40 pM) for the indicated
period. The cells were harvested and assayed for the luciferase activity
using the Dual-Luciferase Reporter Assay System (Promega, Madison,
WI) according to the manufacturers instructions. At least three inde-
pendent experiments were carried out for each assay.
2.3. Immunoprecipitation and immunoblotting
The immunoprecipitation and Western blotting assays were per-
formed as described previously [37]. Human embryonic kidney carci-
noma cell line, 293T, was maintained in DMEM containing 10%
FBS and transfected by the standard calcium precipitation protocol
[37]. The cells were harvested and lysed in lysis buﬀer (50 mM Tris–
HCl, pH 7.4, 0.15 M NaCl, containing 1% NP-40, 1 lM sodium ortho-
vanadate, 1 lM phenylmethylsulfonyl ﬂuoride, and 10 lg/ml each of
aprotinin, pepstatin, and leupeptin). The immunoprecipitates from cell
lysates were resolved on SDS–PAGE and transferred to Immobilon ﬁl-
ter (Millipore; Bedford, MA). The ﬁlters were then immunoblotted
with each antibody. Immunoreactive proteins were visualized using
an enhanced chemiluminescence detection system (Amersham Pharma-
cia Biotech).
2.4. Indirect immunoﬂuorescence
Hep3B cells were maintained in DMEM containing 10% FBS
transfected with FLAG-Smad3 WT, K333R, K341R, K378R or
K409R mutants by using jetPEI. Thirty hours after transfection,
the cells were stimulated by TGF-b (40 pM). Thirty minutes after
stimulation, the cells were ﬁxed with a solution containing 4%
paraformaldehyde and reacted with a rabbit anti-FLAG antibody
(Sigma). The cells were then reacted with a FITC-conjugated anti-
rabbit IgG (Chemicon, Temecula, CA, USA) and observed under a
confocal laser ﬂuorescent microscope. At the same time, the nuclei
in the cells were stained with 4 0,6-diamidino-2-phenylindole (DAPI)
(Wako, Tokyo, Japan). Images were obtained by using a Zeiss
LSM 510 laser scanning microscope with an Apochromat 63·/1.4
oil immersion objective and 4· zoom.
2.5. RT-PCR analysis
After 12 h of culture in 1% FBS, each stably Hep3B transformants
was treated with TGF-b (40 pM) for 2 h. Total RNAs were prepared
by using Iso-Gen (Nippon Gene, Tokyo, Japan) and used in RT-
PCR analysis performed using RT-PCR high -Plus-Kit (TOYOBO,
Tokyo, Japan). Human plasminogen activator inhibitor-1 (PAI-1)
and G3PDH primers were used as described previously [5].3. Results and discussion
3.1. Roles for the lysine residues in the Smad3-MH2 domain in
the activation of TGF-b-mediated transcription
The Smad3-MH2 domain is known to bind to a diverse
group of proteins, which do not contain a common sequence
motif [38]. Our previous studies also demonstrated that PIASy
interacted with Smad3 through its MH2 domain [5]. Further-
more, overexpression of Smad3-MH2 restored the inhibition
by PIASy [5]. We also showed the RING domain of PIASy,
which mediates sumoylation, is important for the suppression
of Smad activity [21]. These ﬁndings led us to examine the roles
for lysine residues in the Smad3-MH2 domain. As shown in
Fig. 1A, there are four lysine residues in the Smad3-MH2 do-
main (Lys-333, Lys-341, Lys-378, and Lys-409). The Smad3-
MH2 domain is well conserved with those of R-Smads and
Fig. 1. Lysine residues in the Smad3-MH2 domain and its mutants. (A) The functional domains of Smad3 are schematically shown. Sequence in the
Smad3-MH2 domain contains four lysine residues shown in bold. The L3 loop is boxed. (B) 293T cells (1 · 107 cells) were transiently transfected with
FLAG-tagged full-length Smad3 (5 lg) or GST-tagged Smad3-MH2 (10 lg) for the Smad3 WT, K333R, K341R, K378R or K409R mutants. Protein
expression levels of the Smad3 WT, K333R, K341R, K378R, and K409R mutants were examined from total lysates (1%) by Western blot with anti-
FLAG or anti-GST antibodies.
Fig. 2. Roles of the lysine residues in the Smad3-MH2 domain in the
activation of TGF-b-mediated transcription. Hep3B cells in a 6-well
plate were transfected with p3TP-LUC (0.5 lg) together with the
Smad3 WT, K333R, K341R, K378R or K409R mutant (0.5 lg).
Thirty-six hours after transfection, the cells were stimulated with TGF-
b (40 pM) for additional 6 h. The stimulated cells were harvested, and
luciferase activities were measured. The results are indicated as fold
induction of luciferase activity from triplicate experiments, and the
error bars represent the S.D.
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strand B8, B9 and the a helix H5 of Smad3, respectively. Lys-
378 in Smad3 is located on the L3 loop that is recognized by
the L45 loop, which is located immediately adjacent to the
Gly/Ser-rich (GS) region of TbR-I [39]. In Smad2, it is re-
ported that a positively charged surface pocket formed by
the L3 loop and the B8 strand, referred to as the loop-strand
pocket, is required for interactions with the activated TbR-I
[40]. Furthermore, B8 and B9 strands have relation with the
interaction of Smad anchor for receptor activation (SARA)
and Smad2 [39]. To elucidate whether the Smad3 K333R,
K341R, K378R, and K409R mutants aﬀect on the TGF-b sig-
naling pathway, we created a series of the full-length Smad3
K333R, K341R, K378R, and K409R mutants of four lysine
residues to arginine residues. We also made GST-Smad3-
MH2 K333R, K341R, K378R or K409R mutants. These mu-
tant proteins expressed well in 293T cells comparable with
wild-type proteins (Fig. 1B). To ﬁrst examine whether these
K333R, K341R, K378R, and K409R mutants have any eﬀect
on TGF-b-mediated transcriptional activation through
Smad3, we performed a transient transcription assay using
Hep3B. The TGF-b-mediated Smad3 transcriptional responses
were measured by p3TP-LUC, which is one of the standard
reporters for assessing TGF-b activity [33]. As shown in Fig.
2, the WT, K333R and K409R mutants induced the transcrip-
tional activation of p3TP-LUC in Hep3B cells by TGF-b.
Importantly, the K409R mutant enhanced more potently than
the WT or K333R mutant. In contrast, both the K378R and
K341R mutants failed to induce the transcriptional activation
of p3TP-LUC. These results suggest that Lys-341 and Lys-378,
but not Lys-333 and Lys-409, in the Smad3-MH2 domain are
essential for activation of TGF-b signals.
3.2. Role for lysine-378 in the interaction of Smad-MH2 domain
with Type-I TGF-b receptor
Phosphorylation-triggered heteromeric assembly between
Smad3 and Smad4 is mediated by the C-terminal MH2 do-main. To investigate whether the Smad3-MH2 K333R,
K341R, K378R, and K409R mutants physically interact with
TbR-I (T204D), 293T cells were transfected with HA-tagged
TbR-I (T204D) and the GST-Smad3-MH2 K333R, K341R,
K378R or K409R mutants. Pull-down assay for the GST-
Smad3-MH2 WT, K333R, K341R, K378R, or K409R mutant
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anti-HA antibody. As shown in Fig. 3A, the GST-Smad3-
MH2 WT, K333R, K341R, and K409R mutants strongly
bound to TbR-I (Fig. 3A). In contrast, the GST-Smad3-
MH2 K378R mutant showed a marked reduction of the
interaction with TbR-I (T204D) (Fig. 3A). Furthermore, phos-Fig. 3. Physical interactions of the Smad3 K333R, K341R, K378R or
K409R mutant with type-I TGF-b receptor. (A) 293 T cells (1 · 107
cells) were transfected with GST-Smad3-MH2 (10 lg) WT, K333R,
K341R, K378R or K409R mutant together with HA-tagged TbR-I
(T204D) (3 lg). Forty-eight hours after transfection, the cells were
lysed, and pull down with glutathione–Sepharose beads (GSH bound),
followed by immunoblotting with anti-HA (upper) or anti-GST
antibody (middle). Total cell lysates (1%) were blotted with anti-HA
antibody (lower) to monitor the expression of TbR-I. (B) 293T cells
(1 · 107 cells) were transfected with GST-Smad3-MH2 (10 lg) WT,
K333R, K341R, K378R or K409R mutant together with HA-tagged
TbR-I (T204D) (3 lg). Forty-eight hours after transfection, the cells
were lysed. Total cell lysates (1%) were blotted with anti-phopsho-
Smad3 (Ser 433/435) (pSmad3) (upper), anti-GST antibody (middle) or
anti-HA antibody (lower). C, 293T cells (1 · 107 cells) were transfected
with GST-Smad3-MH2 (10 lg) WT, K333R, K341R, K378R or
K409R mutant together with FLAG-tagged Smad4 (5 lg). Forty-eight
hours after transfection, the cells were lysed, and pull down with
glutathione–Sepharose beads (GSH bound), followed by immunoblot-
ting with anti-FLAG (upper) or anti-GST antibody (middle). Total cell
lysates (1%) were blotted with anti-FLAG antibody (lower) to monitor
the expression of Smad4.phorylation of Smad3 by TbR-I (T204D) was also aﬀected in
the GST-Smad3-MH2 K378R mutant (Fig. 3B). These results
indicate that Lys-378 is necessary for the interaction with and
phosphorylation by TbR-I (T204D). We next examined
whether the GST-Smad3-MH2 K333R, K341R, K378R, and
K409R mutants physically interact with co-Smad, Smad4. As
shown in Fig. 3C, the GST-Smad3-MH2 K333R, K341R,
K378R, and K409R mutants exhibited the interaction with
Smad4 as well as Smad3-MH2 WT. This result suggests that
the K333R, K341R, K378R, and K409R mutations of
Smad3-MH2 domain have no eﬀect on their association with
Smad4.
3.3. Interactions of the Smad3 K333R, K341R, K378R or
K409R mutant with transcriptional co-factors
Smad3 has also been shown to interact with several tran-
scription factors including c-Jun, c-Fos, ATF-2, and steroid
receptors [41,42]. Notably, transcriptional activity of Smad
proteins depends on co-activators such as CBP/p300 and
co-repressors such as TG-interacting factor (TGIF), Ski, or
SnoN [43]. It has been proposed that these proteins control
transcription by modifying the access to chromatin by acety-
lation (co-activator) or deacetylation (co-repressors) of core
nucleosomal histones. The transcriptional co-activators
p300/CBP interact in a ligand-dependent manner with Smad3
through the MH2 domain [29]. Thus, p300/CBP positively
regulate Smad-mediated transcriptional activation. We ﬁrst
examined whether the K333R, K341R, K378R, and K409R
mutants normally interact with co-activators, p300/CBP in
the GST-pull down or co-immunoprecipitation experiments.
As shown in Fig. 4A–D, the WT, K333R and K409R mu-
tants interacted with p300/CBP, whereas the binding poten-
tial of the K409R mutant was stronger than that of the
WT or the K333R mutant. Therefore, these results may sup-
port the enhanced transcriptional activity of the K409R mu-
tant as shown in Fig. 2. Furthermore, as shown in Fig. 4B
and D, both the K341R and K378R mutants failed to inter-
acted with p300/CBP. Similarly, the GST-Smad3-MH2
K378R mutant could not interact with p300/CBP, although
the GST-Smad3-MH2 K341R mutant exhibited a weak inter-
action with p300/CBP (Fig. 4A and C). These interactions
may cause the lower transcriptional activation as shown in
Fig. 2. We also tested whether these Smad3-p300 interactions
is functional. To this end, we examined acetylation of Smad3
by p300 using anti-acetylated lysine speciﬁc antibody. As
shown in Fig. 4E, the WT, K333R, and K409R mutants were
acetylated in the presence of p300 in 293T cells, whereas no
acetylation of Smad3 was observed in the absence of p300
(data not shown).
We previously demonstrated the physical and functional
interactions between Smads and PIASy through the MH2 do-
main [5]. PIASy inhibited Smad-mediated transcriptional
activation in a dose-dependent manner and mediated
SUMO-1 modiﬁcation of Smads [21]. We then tested whether
PIASy interacts with the K333R, K341R, K378R, and
K409R mutants and mediates sumoylation of them. As
shown in Fig. 5A and B, PIASy associated with the
K333R, K341R, K378R or K409R mutants or GST-
Smad3-MH2 mutants as well as the Smad3 WT. Moreover,
co-expression of PIASy and SUMO-1 together with these
mutants resulted in comparable sumoylation of GST-
Smad3-MH2 mutant proteins with the GST-Smad3-MH2
Fig. 4. Physical and functional interactions of the Smad3 K333R, K341R, K378R or K409R mutant with transcriptional co-activators. (A) 293T
cells (1 · 107 cells) were transfected with GST-Smad3-MH2 (10 lg) WT, K333R, K341R, K378R or K409R mutant together with HA-tagged p300
(15 lg). Forty-eight hours after transfection, the cells were lysed, and pull down with glutathione–Sepharose beads (GSH bound), followed by
immunoblotting with anti-HA (upper) or anti-GST antibody (middle). Total cell lysates (1%) were blotted with anti-HA antibody (lower) to monitor
the expression of p300. (B) 293T cells (1 · 107 cells) were transfected with FLAG-tagged full-length Smad3 (5 lg) WT, K333R, K341R, K378R or
K409R mutant together with FLAG-tagged p300 (15 lg). Forty-eight hours after transfection, the cells were lysed and immunoprecipitated with anti-
FLAG antibody and immnoblotted with anti-HA (upper) or anti-FLAG antibody (middle). Total cell lysates (1%) were blotted with anti-HA
antibody (lower) to monitor the expression of p300. (C) 293T cells (1 · 107 cells) were transfected with GST-Smad3-MH2 (10 lg) WT, K333R,
K341R, K378R or K409R mutant together with CBP (15 lg). Forty-eight hours after transfection, the cells were lysed, and pull down with
glutathione–Sepharose beads (GSH bound), followed by immunoblotting with anti-CBP (upper) or anti-GST antibody (middle). Total cell lysates
(1%) were blotted with anti-CBP antibody (lower) to monitor the expression of CBP. (D) 293T cells (1 · 107 cells) were transfected with FLAG-
tagged full-length Smad3 (5 lg) WT, K333R, K341R, K378R or K409R mutant together with CBP (15 lg). Forty-eight hours after transfection, the
cells were lysed and immunoprecipitated with anti-FLAG antibody and immnoblotted with anti-CBP (upper) or anti-FLAG antibody (middle).
Total cell lysates (1%) were blotted with anti-CBP antibody (lower) to monitor the expression of CBP. E, 293T cells (1 · 107 cells) were transfected
with full-length Smad3 (5 lg) WT, K333R, K341R, K378R, or K409R mutant together with FLAG-tagged p300 (15 lg). Forty-eight hours after
transfection, the cells were lysed and immunoprecipitated with anti-FLAG antibody and immnoblotted with anti-acetylated lysine (Ac-Lys) (upper)
or anti-GST antibody (middle). Total cell lysates (1%) were blotted with anti-HA antibody (lower) to monitor the expression of p300.
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observed in the absence of PIASy (data not shown). These re-
sults indicate that PIASy mediates sumoylation at least two
lysine residues in the Smad3-MH2 domain. Furthermore,
none of these mutants showed a resistance for the
PIASy-mediated suppression of transcriptional activation
(data not shown).We also examined physical interactions with other co-repres-
sors, such as Ski and SMRT. As shown in Fig. 5D, Ski
interacted with all GST-Smad3-MH2 mutants as well as GST-
Smad3 MH2 WT. Interestingly, we found that co-repressor,
SMRT also interacts with Smad3 through the MH2 domain
(Fig. 5E). Like Ski, SMRT interacted with all GST-Smad3-
MH2 mutants as well as GST-Smad3-MH2 WT. We could
Fig. 5. Physical and functional interactions of the Smad3 K333R, K341R, K378R, and K409R mutants with PIASy or transcriptional co-repressors.
(A) 293T cells (1 · 107 cells) were transfected with GST-Smad3-MH2 (10 lg) WT, K333R, K341R, K378R or K409R mutant together with HA-
tagged PIASy (5 lg). Forty-eight hours after transfection, the cells were lysed, and pull down with glutathione–Sepharose beads (GSH bound),
followed by immunoblotting with anti-HA (upper) or anti-GST antibody (middle). Total cell lysates (1%) were blotted with anti-HA antibody
(lower) to monitor the expression of PIASy. (B) 293T cells (1 · 107 cells) were transfected with FLAG-tagged full-length Smad3 (5 lg) WT, K333R,
K341R, K378R, or K409R mutant together with HA-tagged PIASy (15 lg). Forty-eight hours after transfection, the cells were lysed and
immunoprecipitated with anti-FLAG antibody and immnoblotted with anti-HA (upper) or anti-FLAG antibody (middle). Total cell lysates (1%)
were blotted with anti-HA antibody (lower) to monitor the expression of PIASy. (C) 293T cells (1 · 107 cells) were transfected with FLAG-tagged
full-length Smad3 (5 lg) WT, K333R, K341R, K378R, or K409R mutant together with HA-tagged PIASy (15 lg) together with SUMO-1 (5 lg).
Forty-eight hours after transfection, the cells were lysed and immunoprecipitated with anti-FLAG antibody and immnoblotted with anti-FLAG
antibody (upper). Total cell lysates (1%) were blotted with anti-HA antibody (lower) to monitor the expression of PIASy. (D) 293T cells (1 · 107
cells) were transfected with GST-Smad3-MH2 (10 lg) WT, K333R, K341R, K378R or K409R mutant together with Myc-tagged Ski (10 lg). Forty-
eight hours after transfection, the cells were lysed, and pull down with glutathione–Sepharose beads (GSH bound), followed by immunoblotting with
anti-Myc (upper) or anti-GST antibody (middle). Total cell lysates (1%) were blotted with anti-Myc antibody (lower) to monitor the expression of
Ski. (E) 293T cells (1 · 107 cells) were transfected with GST-Smad3-MH2 (10 lg) WT, K333R, K341R, K378R or K409R mutant together with
FLAG-tagged SMRT (5 lg). Forty-eight hours after transfection, the cells were lysed, and pull down with glutathione–Sepharose beads (GSH
bound), followed by immunoblotting with anti-FLAG (upper) or anti-GST antibody (middle). Total cell lysates (1%) were blotted with anti-FLAG
antibody (lower) to monitor the expression of SMRT.
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and K378R mutants to these repressors, suggesting the lower
transcriptional activation of the K341R and K378R mutants
may depend on the interactions with TbR-I or co-activators,
p300/CBP.3.4. Subcellular localization of the Smad3 K333R, K341R,
K378R or K409R mutant
We next assessed the subcellular localization of the
K333R, K341R, K378R, and K409R mutants. Expression
vectors for FLAG-tagged Smad3 WT, K333R, K341R,
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Forty-eight hours after transfection, the cells were ﬁxed
and reacted with anti-FLAG polyclonal antibody, and visu-
alized with an ﬂuorescein isothiocyanate-conjugated anti-
body. As shown in Fig. 6A, the WT and all mutants
localized in the cytoplasm in the absence of TGF-b. Thirty
minutes after stimulation with TGF-b, the WT, K333R, and
K409R mutants translocated into the nucleus. However,
both the K341R and K378R mutants localized in the cyto-
plasm after TGF-b stimulation (Fig. 6A), and no accumula-
tion in the nucleus was observed even after the prolonged
TGF-b-stimulation up to 12 h (data not shown). The time
course analysis of the subcellular localization also demon-
strated that both the K341R and K378R mutants failed to
translocate into nucleus (Fig. 6B). It is reasonable that the
K378R failed to translocate into nucleus because this mu-
tant was not activated by TbR-I (Fig. 3A and B), whereas
the K341R mutant was normally activated by TbR-I. We
next examined the eﬀect of K341R and K378R mutants
on the nuclear translocation of Smad4 in response to
TGF-b, although these mutants could associate with Smad4
(Fig. 3C). Surprisingly, co-expression of Smad4 with these
mutants resulted in the failure of the nuclear translocation
of Smad4 after TGF-b stimulation (Fig. 6C). These results
indicate that Lys-341 and Lys-378, but not Lys-333 and
Lys-409, in the Smad3-MH2 domain are necessary for the
TGF-b-induced nuclear translocation of not only Smad3
but also Smad4 in Hep3B cells. Moreover, Lys-341 may
be a critical residue for the nuclear import of Smad3, since
Lys-341 is not involved in the interaction with TbR-I. Lys-
333, Lys-341, and Lys-378 of Smad3 are highly conserved
not only among all R-Smads but also for the Co-Smad
(Smad4). In addition, Lys-375 and Lys-420 of Smad2 corre-
sponding residues to Lys-333 and Lys-378 of Smad3, di-
rectly coordinate the phosphorylated C-terminus and play
critical roles in hetero-oligomerization [40]. Lys-383 of
Smad2 corresponding to Lys-341 of Smad3, is shown to
form an intermolecular H bond with SARA in association
with SARA [40], suggesting that the K341R mutation of
Smad3 may also aﬀect the interaction with SARA. A previ-
ous study demonstrated that a nuclear localization signal
(NLS) of Smad3 exists in the N-terminal region of
Smad3-MH1 domain [44]. An NLS-like motif was conserved
among all Smads, not only is responsible for constitutive
nuclear localization of the isolated Smad3-MH1 domain
but also is crucial for Smad3 nuclear import in response
to TGF-b. Mutations in this motif completely abolished
TGF-b-induced Smad3 nuclear translocation. Furthermore,
the Smad3 mutants with the NLS mutations are domi-
nant-negative inhibitors of TGF-b-induced transcriptional
activation. The isolated Smad3-MH1 domain was also dem-
onstrated to display the speciﬁc binding to importin-b,
which is diminished or eliminated by mutations in the
NLS [45]. Full-length Smad3 exhibited weak but speciﬁc
binding to importin-b, which is enhanced after phosphoryla-
tion by TbR-I [45]. Moreover, it has been recently shown
that the nuclear import of Smad3 is dependent on the inter-
action with FG-repeat-containing nucleoporins such as
CAN/Nup214 [46]. A surface hydrophobic corridor within
the MH2 domain of Smad3 is also shown to be critical
for association with CAN/Nup214 and the nuclear import.
These ﬁndings suggest that the K341R mutant may partlyparticipate in a surface hydrophobic corridor. Further de-
tailed analysis of this K341R mutant will be very useful
to understand the nuclear import mechanisms for Smad3
and Smad4.3.5. Both the Smad3 K341R and K378R mutants act as
dominant-negative inhibitors of TGF-b-induced
transcriptional activation
We further examined whether the K333R, K341R, K378R,
and K409R mutants act as dominant-negative inhibitors of
TGF-b-induced transcriptional activation. To examine the
eﬀect of the K333R, K341R, K378R, and K409R mutants
on the TGF-b-signaling pathway under more physiological
conditions through endogenous proteins, we established the
stable transformants expressing the WT, K333R, K341R,
K378R or K409R mutant in Hep3B cells (Fig. 7A). In
Hep3B cells, TGF-b treatment induced Smad3-mediated
PAI-1 expression [5]. We then tested endogenous PAI-1
mRNA expression in these transformants by TGF-b. As
shown in Fig. 7B, when we monitored the RNA samples
by RT-PCR, endogenous PAI-1 mRNA expression by
TGF-b was the markedly decreased in transformants with
the K341R or K378R mutants, but not in those with the
WT, K333R, or K409R. These results suggest that both
the K341R and K378R mutants act as dominant-negative
inhibitors of TGF-b-induced transcriptional activation in
Hep3B cells.
Smad-MH2 domain is known to be sensitive to mutations.
Gly-421 in Smad2-MH2 domain is a highly conserved gly-
cine residue whose mutation to serine in Drosophila Mad
[47] or to aspartic acid in Caenorhabditis elegans Sma-2
[48] causes null or severe developmental phenotypes. The
corresponding mutation in Smad1 inhibits BMP-induced
phosphorylation of Smad1 [49]. In Smad2, the G421S muta-
tion inhibited Smad2 binding to the receptor and TGF-b-
dependent phosphorylation [50]. As shown in Fig. 3A and
B, Smad3 K378R mutant exhibited the similar defect with
Smad2 G421S mutant, since Lys-378 of Smad3 is adjacent
to Gly-379 corresponding to Smad2 Gly-421. A missense
mutation of Asp-450 to Glu (D450E) in Smad2-MH2 do-
main was also reported in a case of colorectal cancer. This
mutant was reported to be defective in phosphorylation by
TbR-I [51]. Asp-537 of Smad4 corresponding to Asp-450
of Smad2 was located at an interface of oligomer formation,
and the Smad4 D537E mutant, as well as Smad2 D450E,
was defective in oligomerization [40,52]. Similarly, Smad3
D407E mutant was not phosphorylated by TbR-I, and
inhibited the phosphorylation of wild-type Smad2 and
Smad3 as a dominant-negative protein [53].
Our present ﬁndings revealed that Lys-378 is necessary for
interaction with and phosphorylation by TbR-I, suggesting
that Lys-378 is a critical residue for Smad3 activation. Impor-
tantly, Smad3 K341R mutant failed in nuclear translocation,
indicating that Lys-341 is required for nuclear import of
Smad3. In contrast, the K409R mutant enhanced transcrip-
tional activity through a stronger interaction with co-activa-
tors, p300/CBP, suggesting that Lys-409 is also involved in
the regulation of TGF-b-mediated transcription. Thus, the
present study indicates that lysine residues in the MH2
domain of Smad3 may play important roles in TGF-b signaling
pathway.
Fig. 6. Subcellular localization of the Smad3 K333R, K341R, K378R or K409R mutant in TGF-b-stimulated Hep3B cells. (A) Hep3B cells were
transfected with FLAG-tagged Smad3 WT, K333R, K341R, K378R or K409R mutant. Thirty hours after transfection, cells were stimulated with
TGF-b (40 pM) for 30 min, and then ﬁxed and reacted with rabbit anti-FLAG polyclonal antibody and visualized with ﬂuorescein isothiocyanate-
conjugated anti-rabbit antibody. The same slide was also stained with DAPI for the nuclei staining. (B) Hep3B cells were transfected with FLAG-
tagged Smad3 WT, K333R, K341R, K378R or K409R mutant. Thirty hours after transfection, cells were stimulated with TGF-b (40 pM) for the
indicated periods. Quantitative analysis of the subcellular localization of Smad3. Approximately 100 cells were classiﬁed according ﬂuorescein signals
in the cytoplasm (yellow), cytoplasm and nucleus (red) and nucleus (blue). The results represent the means of three individual experiments, in which
100 cells were counted. (C) Hep3B cells were transfected with FLAG-tagged Smad4 together with Myc-tagged Smad3 WT, K341R or K378R
mutant. Thirty hours after transfection, cells were stimulated with TGF-b (40 pM) for 30 min, and then ﬁxed and reacted with anti-FLAG polyclonal
antibody and anti-Myc monoclonal antibody, and visualized with ﬂuorescein isothiocyanate-conjugated anti-rabbit antibody and rhodamine-
conjugated anti-mouse antibody. The same slide was also stained with DAPI for the nuclei staining.
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Fig. 7. Both the Smad3 K341R and K378R mutants act as dominant-negative inhibitors of TGF-b-induced transcriptional activation. (A) Stable
Hep3B transformants expressing the Smad3 WT, K333R, K341R, K378R or K409R mutant were established. Total extracts (1%) of each
transformant were examined with Western blot using anti-FLAG antibody to monitor the expression of the Smad3 WT, K333R, K341R, K378R or
K409R mutant. (B) Stable Hep3B cell transformants were treated or untreated with TGF-b (40 pM) for 2 h. Total RNA samples isolated from these
cells were subjected to RT-PCR analysis using PAI-1 (upper panels) and glyceraldehydes-3-phosphate dehydrogenase (G3PDH) (lower panels)
primers. RT-PCR products were separated on a 1% agarose gel. This ﬁgure is representative of three separate experiments.
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